{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:04:53Z","timestamp":1784325893037,"version":"3.55.0"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Anti-myelin-associated glycoprotein (MAG) neuropathy is a rare autoimmune neuropathy that preferentially affects the myelin of distal fibers. This distal demyelination and secondary axon loss lead to its characteristic clinical features of distal sensory loss and weakness, upper limb tremor, and ataxia, leading to significant disability for the patient. Diagnosis is predicated on its distinct electrodiagnostic and serological profile of distally accentuated demyelination and high IgM anti-MAG antibody titers. Accurate diagnosis of anti-MAG neuropathy is critical, as standard CIDP therapies do not work, but some novel treatments like Bruton tyrosine kinase inhibitors may prove effective. Currently, rituximab is the most frequently used treatment, despite current evidence showing benefit in only a subset of patients. This review highlights the value of gait analysis in the clinical and research assessment of anti-MAG neuropathy, using existing quality of life-based data. The unique pathophysiology and clinical features of anti-MAG neuropathy create specific rehabilitation challenges, making awareness of this disorder critical for electromyographers and those treating neuropathies in all settings.<\/jats:p>","DOI":"10.1097\/phm.0000000000002957","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:00:36Z","timestamp":1784325636000},"page":"747-756","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Anti-MAG Neuropathy"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-3099","authenticated-orcid":false,"given":"Shawn P.","family":"Jorgensen","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Albany Medical College, Albany, New York"},{"name":"Department of Neurology, Larner Medical College at the University of Vermont, Burlington, Vermont"},{"name":"Adirondack Rehabilitation Medicine, Queensbury, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan L.","family":"McNeish","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan"},{"name":"Department of Neurology, University of Michigan, Ann Arbor, Michigan"},{"name":"Institute of Gerontology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiley C.","family":"Whalen","sequence":"additional","affiliation":[{"name":"Adirondack Rehabilitation Medicine, Queensbury, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe A.","family":"Sowers","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kolb","sequence":"additional","affiliation":[{"name":"Department of Neurology, Larner Medical College at the University of Vermont, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro M.","family":"Stino","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"R1-20260717","doi-asserted-by":"crossref","first-page":"577725","DOI":"10.1016\/j.jneuroim.2021.577725","article-title":"Anti-MAG neuropathy: from biology to clinical management","volume":"361","author":"Steck","year":"2021","journal-title":"J Neuroimmunol"},{"key":"R2-20260717","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mus.27954","article-title":"Anti\u2013myelin-associated glycoprotein neuropathy: where do we stand?","volume":"68","author":"Stino","year":"2023","journal-title":"Muscle Nerve"},{"key":"R3-20260717","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/WCO.0000000000000975","article-title":"Antibody testing in neuropathy associated with anti-myelin-associated glycoprotein antibodies: where we are after 40 years","volume":"34","author":"Latov","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"R4-20260717","first-page":"1","article-title":"Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials. [Neuropatia anti-MAG: aspectos hist\u00f3ricos, correla\u00e7\u00f5es cl\u00ednico-patol\u00f3gicas e considera\u00e7\u00f5es para ensaios terap\u00eauticos futuros]","volume":"82","author":"Latov","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"key":"R5-20260717","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"R6-20260717","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: Clinicopathological and therapeutic features","volume":"89","author":"Svahn","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R7-20260717","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/BF00878529","article-title":"Neuropathy associated with \u2018benign\u2019 anti-myelin associated glycoprotein IgM gamopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases","volume":"243","author":"Ellie","year":"1996","journal-title":"J Neurol"},{"key":"R8-20260717","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ene.16249","article-title":"Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: a nationwide survey study of 133 patients","volume":"31","author":"Aotsuka","year":"2024","journal-title":"Eur J Neurol"},{"key":"R9-20260717","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s10072-017-3133-0","article-title":"Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein","volume":"38","author":"Sakamoto","year":"2017","journal-title":"Neurol Sci"},{"key":"R10-20260717","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CND.0000000000000525","article-title":"Clinical and electrodiagnostic findings in anti-myelin\u2013associated glycoprotein antibody polyneuropathy: a single center review","volume":"26","author":"Nardin","year":"2025","journal-title":"J Clin Neuromuscul Dis"},{"key":"R11-20260717","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/mus.880131205","article-title":"The electrodiagnostic findings in polyneuropathies associated with IGM monoclonal gammopathies","volume":"13","author":"Kelly","year":"1990","journal-title":"Muscle Nerve"},{"key":"R12-20260717","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM198009113031105","article-title":"Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin","volume":"303","author":"Latov","year":"1980","journal-title":"N Engl J Med"},{"key":"R13-20260717","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.21741","article-title":"IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy","volume":"42","author":"Kawagashira","year":"2010","journal-title":"Muscle Nerve"},{"key":"R14-20260717","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1097-4598(199701)20:1<38::AID-MUS5>3.0.CO;2-I","article-title":"Physiological tremor analysis of patients with anti-myelin-associated glycoprotein associated neuropathy and tremor","volume":"20","author":"Pedersen","year":"1997","journal-title":"Muscle Nerve"},{"key":"R15-20260717","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clinph.2023.12.005","article-title":"Upper and lower limb tremor in inflammatory neuropathies","volume":"158","author":"Silsby","year":"2024","journal-title":"Clin Neurophysiol"},{"key":"R16-20260717","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/mus.27542","article-title":"Nerve ultrasound characteristics of immunoglobulin M neuropathy associated with anti-myelin-associated glycoprotein antibodies","volume":"65","author":"Oka","year":"2022","journal-title":"Muscle Nerve"},{"key":"R17-20260717","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"key":"R18-20260717","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/450391","article-title":"Heterogeneity of polyneuropathy associated with anti-MAG antibodies","volume":"2015","author":"Magy","year":"2015","journal-title":"J Immunol Res"},{"key":"R19-20260717","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.nmd.2017.08.001","article-title":"230th ENMC International Workshop","volume":"27","author":"Pruppers","year":"2017","journal-title":"Neuromuscul Disorders"},{"key":"R20-20260717","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.20678","article-title":"Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins","volume":"35","author":"Lupu","year":"2007","journal-title":"Muscle Nerve"},{"key":"R21-20260717","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/jnnp-2024-334678","article-title":"Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management","volume":"96","author":"Min","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R22-20260717","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1212\/01.wnl.0000336370.51010.a1","article-title":"Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation","volume":"72","author":"England","year":"2009","journal-title":"Neurology"},{"key":"R23-20260717","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"R24-20260717","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/mus.24768","article-title":"Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy","volume":"52","author":"Naddaf","year":"2015","journal-title":"Muscle Nerve"},{"key":"R25-20260717","first-page":"119","article-title":"POEMS syndrome: diagnosis and investigative work-up","volume":"32","author":"Dispenzieri","year":"2018","journal-title":"Hematol Clin"},{"key":"R26-20260717","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1388-2457(01)00469-2","article-title":"Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathy","volume":"112","author":"Attarian","year":"2001","journal-title":"Clin Neurophysiol"},{"key":"R27-20260717","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1388-2457(02)00011-1","article-title":"Can electrophysiology differentiate polyneuropathy with anti-MAG\/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?","volume":"113","author":"Capasso","year":"2002","journal-title":"Clin Neurophysiol"},{"key":"R28-20260717","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/brain\/117.5.941","article-title":"Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside","volume":"117","author":"Kaku","year":"1994","journal-title":"Brain"},{"key":"R29-20260717","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/mus.1145","article-title":"Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody","volume":"24","author":"Cocito","year":"2001","journal-title":"Muscle Nerve"},{"key":"R30-20260717","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/jnnp.2006.111930","article-title":"Anti-MAG\/SGPG associated neuropathy does not commonly cause distal nerve temporal dispersion","volume":"78","author":"Gondim","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R31-20260717","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1030::AID-MUS4>3.0.CO;2-H","article-title":"Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening","volume":"22","author":"Ritz","year":"1999","journal-title":"Muscle Nerve"},{"key":"R32-20260717","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/NEN.0b013e3181fa44af","article-title":"Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy","volume":"11","author":"Kawagashira","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"R33-20260717","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.410330514","article-title":"Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein","volume":"33","author":"Tatum","year":"1993","journal-title":"Ann Neurol"},{"key":"R34-20260717","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/WCO.0000000000001407","article-title":"Nerve ultrasound in the diagnosis of inflammatory neuropathies","volume":"38","author":"Leonardi","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"R35-20260717","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1038\/s41598-024-54452-8","article-title":"Typical CIDP, distal variant CIDP, and anti-MAG antibody neuropathy: an ultra-high frequency ultrasound comparison of nerve structure","volume":"14","author":"Puma","year":"2024","journal-title":"Sci Rep"},{"key":"R36-20260717","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ene.12554","article-title":"Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies","volume":"22","author":"Lucchetta","year":"2014","journal-title":"Eur J Neurol"},{"key":"R37-20260717","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mus.1149","article-title":"MRI of the brachial plexus in polyneuropathy associated with monoclonal gammopathy","volume":"24","author":"Eurelings","year":"2001","journal-title":"Muscle Nerve"},{"key":"R38-20260717","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0044-1791769","article-title":"Top 10 clinical pearls in paraproteinemic neuropathies","volume":"45","author":"Becker","year":"2025","journal-title":"Semin Neurol"},{"key":"R39-20260717","doi-asserted-by":"crossref","first-page":"577288","DOI":"10.1016\/j.jneuroim.2020.577288","article-title":"Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy","volume":"345","author":"Liberatore","year":"2020","journal-title":"J Neuroimmunol"},{"key":"R40-20260717","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"R41-20260717","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41598-019-42545-8","article-title":"Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy","volume":"9","author":"Pascual-Go\u00f1i","year":"2019","journal-title":"Sci Rep"},{"key":"R42-20260717","doi-asserted-by":"crossref","first-page":"e210000","DOI":"10.1212\/WNL.0000000000210000","article-title":"Optimizing anti-myelin-associated glycoprotein and IgM-gammopathy testing for neuropathy treatment evaluation","volume":"103","author":"Klein","year":"2024","journal-title":"Neurology"},{"key":"R43-20260717","doi-asserted-by":"crossref","first-page":"e200122","DOI":"10.1212\/NXI.0000000000200122","article-title":"Mutational profile in 75 patients with anti-myelin-associated glycoprotein neuropathy: clinical and hematologic therapy response and hints on new therapeutic targets","volume":"10","author":"Castellani","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R44-20260717","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00415-023-12068-4","article-title":"Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy","volume":"271","author":"Gu\u00e9r\u00e9my","year":"2024","journal-title":"J Neurol"},{"key":"R45-20260717","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"R46-20260717","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/jns.12547","article-title":"IgM anti-MAG\u00b1 peripheral neuropathy (IMAGiNe) study protocol: an international, observational, prospective registry of patients with IgM M-protein peripheral neuropathies","volume":"28","author":"Hamadeh","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"R47-20260717","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00415-019-09618-0","article-title":"Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort","volume":"267","author":"Tang","year":"2020","journal-title":"J Neurol"},{"key":"R48-20260717","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2014.11.006","article-title":"Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody","volume":"348","author":"Kawagashira","year":"2015","journal-title":"J Neurol Sci"},{"key":"R49-20260717","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"key":"R50-20260717","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"R53-20260717","doi-asserted-by":"crossref","first-page":"123626","DOI":"10.1016\/j.jns.2025.123626","article-title":"Reversible rituximab demyelination in anti-MAG polyneuropathy; a role for IVIG?","volume":"476","author":"Mak","year":"2025","journal-title":"J Neurol Sci"},{"key":"R54-20260717","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Comi","year":"2002","journal-title":"J Neurol"},{"key":"R55-20260717","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"R56-20260717","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"N Engl J Med"},{"key":"R57-20260717","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.61.1.36","article-title":"Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients","volume":"61","author":"Maisonobe","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R58-20260717","doi-asserted-by":"crossref","first-page":"e16164","DOI":"10.1111\/ene.16164","article-title":"Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: a phase 1 study to identify the maximum tolerated dose","volume":"31","author":"Stino","year":"2024","journal-title":"Eur J Neurol"},{"key":"R59-20260717","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R60-20260717","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2522\/ptj.20090125","article-title":"Dynamic principles of gait and their clinical implications","volume":"90","author":"Kuo","year":"2010","journal-title":"Phys Ther"},{"key":"R61-20260717","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0166-2236(02)02173-2","article-title":"The special nature of human walking and its neural control","volume":"25","author":"Capaday","year":"2002","journal-title":"Trends Neurosci"},{"key":"R62-20260717","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/dmrr.809","article-title":"Gait characteristics of diabetic patients: a systematic review","volume":"24","author":"Allet","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"R63-20260717","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clinbiomech.2007.10.004","article-title":"An exploration of step time variability on smooth and irregular surfaces in older persons with neuropathy","volume":"23","author":"Richardson","year":"2008","journal-title":"Clin Biomech"},{"key":"R64-20260717","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s13300-017-0295-y","article-title":"Diabetic neuropathy and gait: a review","volume":"8","author":"Alam","year":"2017","journal-title":"Diabetes Ther"},{"key":"R65-20260717","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4187\/respcare.03480783","article-title":"The six-minute walk test","volume":"48","author":"Enright","year":"2003","journal-title":"Respir Care"},{"key":"R66-20260717","first-page":"816","article-title":"Six-minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen","volume":"70","author":"Govoni","year":"2024","journal-title":"Muscle Nerve"},{"key":"R67-20260717","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00415-019-09207-1","article-title":"Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP","volume":"266","author":"Spina","year":"2019","journal-title":"J Neurol"},{"key":"R68-20260717","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1007\/s00415-018-9081-7","article-title":"Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies","volume":"265","author":"Falzone","year":"2018","journal-title":"J Neurol"},{"key":"R69-20260717","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"R70-20260717","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jns.12197","article-title":"Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study","volume":"22","author":"Delmont","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"R71-20260717","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12603-011-0062-0","article-title":"Timed Up and Go test and risk of falls in older adults: a systematic review","volume":"15","author":"Beauchet","year":"2011","journal-title":"J Nutr Health Aging"},{"key":"R72-20260717","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/ageing\/afs099","article-title":"Performance-based physical function in older community-dwelling persons: a systematic review of instruments","volume":"41","author":"Freiberger","year":"2012","journal-title":"Age Ageing"},{"key":"R73-20260717","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res Manag"},{"key":"R74-20260717","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mus.20341","article-title":"Muscle cramps","volume":"32","author":"Miller","year":"2005","journal-title":"Muscle Nerve"},{"key":"R75-20260717","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/ene.13459","article-title":"Prevalence, correlates and impacts of pain and cramps in anti-MAG neuropathy: a multicentre European study","volume":"25","author":"Rajabally","year":"2018","journal-title":"Eur J Neurol"},{"key":"R76-20260717","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1212\/WNL.0b013e3181f003be","article-title":"Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"75","author":"Katzberg","year":"2010","journal-title":"Neurology"},{"key":"R77-20260717","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1212\/WNL.0000000000002507","article-title":"A randomized trial of mexiletine in ALS","volume":"86","author":"Weiss","year":"2016","journal-title":"Neurology"},{"key":"R78-20260717","first-page":"CD008943","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults","volume":"2012","author":"Chaparro","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R79-20260717","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jns.2016.12.029","article-title":"Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy","volume":"373","author":"Doneddu","year":"2017","journal-title":"J Neurol Sci"},{"key":"R80-20260717","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s10072-025-08087-w","article-title":"Acute onset anti-MAG neuropathy and paradoxical worsening to rituximab: a challenging case","volume":"46","author":"Cassano","year":"2025","journal-title":"Neurol Sci"},{"key":"R81-20260717","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.gaitpost.2013.11.013","article-title":"Sensory loss and walking speed related factors for gait alterations in patients with peripheral neuropathy","volume":"39","author":"Wuehr","year":"2014","journal-title":"Gait Posture"},{"key":"R82-20260717","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/apmr.2001.19742","article-title":"A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy","volume":"82","author":"Richardson","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"key":"R83-20260717","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/mus.22325","article-title":"Frontal plane hip and ankle sensorimotor function, not age, predicts unipedal stance time","volume":"45","author":"Allet","year":"2012","journal-title":"Muscle Nerve"},{"key":"R84-20260717","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/mus.28208","article-title":"Approach to gait disorders and orthotic management in adult onset neuromuscular diseases","volume":"71","author":"Chiou-Tan","year":"2025","journal-title":"Muscle Nerve"},{"key":"R85-20260717","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s004210050558","article-title":"Central and peripheral contributions to muscle fatigue in humans during sustained maximal effort","volume":"80","author":"Kent-Braun","year":"1999","journal-title":"Eur J Appl Physiol"},{"key":"R86-20260717","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/0883073813493663","article-title":"Weakness and fatigue in diverse neuromuscular diseases","volume":"28","author":"Montes","year":"2013","journal-title":"J Child Neurol"},{"key":"R87-20260717","first-page":"CD006788","article-title":"Pharmacological treatments for fatigue associated wtih palliative care","volume":"5","author":"Mucke","year":"2015","journal-title":"Cochrane Database Syst Rev"}],"container-title":["American Journal of Physical Medicine &amp; Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PHM.0000000000002957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:00:47Z","timestamp":1784325647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PHM.0000000000002957"}},"subtitle":["Disease Overview, Gait Characteristics, and Rehabilitation Needs"],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/phm.0000000000002957","relation":{},"ISSN":["0894-9115","1537-7385"],"issn-type":[{"value":"0894-9115","type":"print"},{"value":"1537-7385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2025-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}